Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Human immunodeficiency virus 1 | Human immunodeficiency virus type 1 reverse transcriptase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Trypanosoma congolense | RNA helicase, putative | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Plasmodium yoelii | integrase-related | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Trypanosoma brucei | RNA helicase, putative | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Schistosoma mansoni | hypothetical protein | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0157 | 0.5331 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0157 | 0.5331 | 0.5 |
Brugia malayi | Carboxylesterase family protein | 0.0157 | 0.5331 | 0.5 |
Echinococcus multilocularis | acetylcholinesterase | 0.0157 | 0.5331 | 0.5 |
Echinococcus multilocularis | acetylcholinesterase | 0.0157 | 0.5331 | 0.5 |
Loa Loa (eye worm) | carboxylesterase | 0.0157 | 0.5331 | 0.5 |
Brugia malayi | Carboxylesterase family protein | 0.0157 | 0.5331 | 0.5 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0157 | 0.5331 | 0.5 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0157 | 0.5331 | 0.5331 |
Loa Loa (eye worm) | hypothetical protein | 0.0157 | 0.5331 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.0157 | 0.5331 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.0157 | 0.5331 | 0.5 |
Trypanosoma brucei | RNA helicase, putative | 0.01 | 0 | 0.5 |
Echinococcus granulosus | carboxylesterase 5A | 0.0157 | 0.5331 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | = 0.004 uM | Tested for the inhibition of wild type HIV-1 (IIIB) replication in MT-4 cells | ChEMBL. | 8863804 |
ED50 (functional) | = 0.004 uM | Tested for the inhibition of wild type HIV-1 (IIIB) replication in MT-4 cells | ChEMBL. | 8863804 |
ED50 (functional) | = 0.005 uM | Inhibition of mutant type (Cys181) HIV-1 (IIIB) replication in MT-4 cells | ChEMBL. | 8863804 |
ED50 (functional) | = 0.005 uM | Inhibition of mutant type (Cys181) HIV-1 (IIIB) replication in MT-4 cells | ChEMBL. | 8863804 |
ED50 (functional) | = 0.04 uM | Inhibition of mutant type (Ile100) HIV-1 (IIIB) replication in MT-4 cells | ChEMBL. | 8863804 |
ED50 (functional) | = 0.04 uM | Inhibition of mutant type (Ile100) HIV-1 (IIIB) replication in MT-4 cells | ChEMBL. | 8863804 |
ED50 (functional) | = 3 uM | Inhibition of HIV-1(IIIB) variants (Ile100/Cys181) in HIV-1 MT-4 cells | ChEMBL. | 8863804 |
ED50 (functional) | = 3 uM | Inhibition of HIV-1(IIIB) variants (Ile100/Cys181) in HIV-1 MT-4 cells | ChEMBL. | 8863804 |
ED50 (functional) | > 10 uM | Inhibition of HIV-1(IIIB) variants (Ile100/Asn103) in HIV-1 MT-4 cells | ChEMBL. | 8863804 |
ED50 (functional) | > 10 uM | Inhibition of HIV-1(IIIB) variants (Ile100/Asn103) in HIV-1 MT-4 cells | ChEMBL. | 8863804 |
IC50 (binding) | = 0.002 uM | Tested for the inhibition of wild type HIV-1 (IIIB) RT | ChEMBL. | 8863804 |
IC50 (binding) | = 0.002 uM | Tested for the inhibition of wild type HIV-1 (IIIB) RT | ChEMBL. | 8863804 |
IC50 (binding) | = 0.14 uM | Tested for the inhibition of mutant type (Ile100) HIV-1 (IIIB) RT | ChEMBL. | 8863804 |
IC50 (binding) | = 0.14 uM | Tested for the inhibition of mutant type (Ile100) HIV-1 (IIIB) RT | ChEMBL. | 8863804 |
IC50 (binding) | = 0.21 uM | Tested for the inhibition of mutant type (Cys181) HIV-1 (IIIB) RT | ChEMBL. | 8863804 |
IC50 (binding) | = 0.21 uM | Tested for the inhibition of mutant type (Cys181) HIV-1 (IIIB) RT | ChEMBL. | 8863804 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.